Pulse Biosciences Inc. (PLSE) shares surged to an all-time high of $48.92 on Friday, extending a year-to-date gain of 248% and a 186.1% increase over the past 12 months. The rally pushed the company's market capitalization to $3.46 billion.
The biotechnology firm, which is developing Nanosecond Pulsed Field Ablation technology for medical applications, has seen its valuation expand rapidly despite ongoing losses. Revenue for the current year is projected to surge 429%, though the company remains unprofitable. Second-quarter 2026 results fell short of expectations, with adjusted losses per share of $0.36 versus a forecasted $0.28 loss, and revenue of $400,000 missing the $600,000 target.
Clinical progress has supported investor optimism. Pulse Biosciences reported faster enrollment in its pivotal atrial fibrillation trial and continued advancement in thyroid and surgical programs. Analysts have largely maintained positive outlooks, with Needham initiating coverage with a buy rating, citing the technology's potential. Canaccord raised its price target from $32 to $43 while retaining a buy rating, emphasizing clinical and regulatory milestones.
Valuation concerns have emerged alongside the stock's rapid ascent. InvestingPro analysis indicates the shares are trading above fair value, listed among the platform's most overvalued stocks, and approaching 52-week high territory. The Relative Strength Index also suggests overbought conditions.
